Article info

Download PDFPDF

Original research
Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors

Authors

  1. Correspondence to Dr Thomas Kelleher; Thomas.Kelleher90{at}gmail.com
View Full Text

Citation

Kelleher T, Cai J, Botwood NA, et al
Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors

Publication history

  • Accepted November 24, 2020
  • First published February 8, 2021.
Online issue publication 
February 08, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.